Intriguingly, KRAS G12C inhibition has also been shown to expand tertiary lymphoid structures (TLS; ref. 56), which are associated with immunotherapy response in multiple solid cancers (57), and boost the production of protective tumor-binding antibodies. The gene discussed is KRAS; the disease is neoplasm.